Dataset related to article "Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment"

This record contains raw data related to article "Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment" ABSTRACT: BACKGROUND: The incidence of glioblastoma among elderly patients is constantly increasing. The value of radiation therapy and concurrent/adjuvant chemotherapy has been widely assessed. So far, the role of surgery has not been thoroughly investigated. The study aimed to evaluate safety and impact of several entities of surgical resection on outcome of elderly patients with newly diagnosed glioblastoma treated by a multimodal approach. METHODS: Patients ≥ 65 years, underwent surgery were included. The extent of surgical resection (EOR) was defined as complete resection (CR = 100%), gross total resection (GTR = 90-99%), sub-total resection (STR = 78-90%), partial resection (PR = 30-78%), and biopsy. After surgery, all patients received adjuvant radiotherapy (60/2 Gy fraction) with concomitant/adjuvant temozolomide chemotherapy. RESULTS: From March 2004 to December 2015, 178 elderly with a median age of 71 years (range 65-83 years) were treated. CR was obtained in 8 (4.5%), GTR in 63 (35.4%), STR in 46 (25.8%), PR in 16 (9.0%), and biopsy in 45 (25.3%). RT was started in all patients, concurrent/adjuvant CHT in 149 (83.7%) and 132 (74.2%). The median follow-up time was 12.2 months (range 0.4-50.4 months). The median, 1- and 2-year progression-free survival was 8.9 months (95%CI 7.8-100 months), 32.0 ± 3.5%, and 12.9 ± 2.6%. The median, 1- and 2-year overall survival were 12.2 (95%CI 11.3-13.1 months), 51.1 ± 3.7%, and 16.3 ± 2.9%. Tumor location, extent of resection, and neurological status after surgery statistically affected survival (p ≪ 0.01). CONCLUSION: Maximal surgical resection is safe and feasible in elderly patients with influence on survival. A preoperative evaluation has to be carried out.本数据集包含与论文《老年新发胶质母细胞瘤（glioblastoma）患者手术切除是否有益？预后评估与预后因素分析》相关的原始数据。 **摘要** **背景**：老年患者胶质母细胞瘤的发病率持续上升。放射治疗（radiation therapy, RT）及同步/辅助化疗的临床价值已得到广泛评估，但截至目前，手术治疗的作用尚未得到充分研究。本研究旨在评估多模态治疗方案下，不同程度手术切除的安全性及其对老年新发胶质母细胞瘤患者预后的影响。 **方法**：纳入年龄≥65岁且接受手术治疗的患者。手术切除范围（extent of surgical resection, EOR）分为完全切除（complete resection, CR = 100%）、大体全切除（gross total resection, GTR = 90%~99%）、次全切除（sub-total resection, STR = 78%~90%）、部分切除（partial resection, PR = 30%~78%）及活检术。所有患者术后均接受辅助放射治疗（60 Gy/2 Gy分割剂量）联合同步/辅助替莫唑胺（temozolomide）化疗。 **结果**：2004年3月至2015年12月期间，共纳入178例老年患者，中位年龄为71岁（范围65~83岁）。其中8例（4.5%）实现完全切除，63例（35.4%）实现大体全切除，46例（25.8%）行次全切除，16例（9.0%）行部分切除，45例（25.3%）仅行活检。所有患者均启动放射治疗，149例（83.7%）接受同步/辅助化疗，132例（74.2%）接受辅助化疗。中位随访时间为12.2个月（范围0.4~50.4个月）。中位无进展生存期（progression-free survival, PFS）为8.9个月（95%置信区间7.8~100个月），1年和2年无进展生存率分别为32.0±3.5%和12.9±2.6%。中位总生存期（overall survival, OS）为12.2个月（95%置信区间11.3~13.1个月），1年和2年总生存率分别为51.1±3.7%和16.3±2.9%。肿瘤位置、切除范围及术后神经功能状态对患者生存具有统计学显著影响（p≪0.01）。 **结论**：对于老年新发胶质母细胞瘤患者，最大化手术切除安全可行，且可改善患者生存预后，术前需进行充分评估。